The global allogeneic cell therapy market was valued at USD 1.95 billion in 2025. The market is estimated at USD 2.30 billion in 2026 and is projected to reach USD 14.50 billion by 2036, at a CAGR of 20.2% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering approved donor-derived products, immunology and cell persistence, manufacturing economics, access and delivery, regulation and reimbursement, pricing, the competitive landscape, and future growth opportunities.
The market includes therapies made from donor cells instead of the patient's own cells, spanning T cell, natural killer (NK) cell, mesenchymal stromal cell, blood-forming stem and progenitor cell, dendritic cell, and islet cell products, along with corneal, chondrocyte, and keratinocyte tissue preparations. Cord blood units are counted only when released as licensed therapeutic products, and a product given with conditioning or supportive medicines is counted at the value of the cell product alone. Autologous cell therapies, gene therapies without a cell product, transfusion and plasma products, organ transplants, transplants of unmanipulated marrow or blood stem cells, private cord blood storage, manufacturing supplies, and the care delivered around treatment are excluded.
According to the FDA's list of approved cellular and gene therapy products, all seven approved CAR-T products, including Kymriah, Yescarta, and Carvykti, are autologous, and no allogeneic CAR-T therapy has been approved. FDA-approved donor-derived products are instead cord blood units, processed tissue products such as StrataGraft and Symvess, the islet cell therapy Lantidra, Omisirge, the mesenchymal stromal cell therapy Ryoncil, and the regulatory T cell immunotherapy Tregzi. The FDA approved Ryoncil in December 2024 for children with steroid-refractory acute graft versus host disease, describing it as the first approved mesenchymal stromal cell therapy; the approval rested on a single-arm study of 54 pediatric patients, 70% of whom responded by day 28. Revenue therefore comes mostly from classes other than the off-the-shelf CAR-T concept that draws most investment.
Immune rejection is the main restraint wherever cells must engraft and persist, as in CAR-T therapy, the most valuable class in cell therapy. Editing out the T cell receptor and using stronger lymphodepletion add toxicity, yet persistence still trails autologous products, and the barrier is biological, so manufacturing experience does not remove it. Donor dependence also narrows the cost advantage of products not made from iPSC lines, since each new donor brings qualification, testing, and comparability work. Developers must further prove durable responses against autologous products with years of follow-up and win reimbursement when lower production cost does not set a price on its own.
NK cell products are a leading opportunity, since NK cells avoid the graft versus host disease risk of donor T cells, need no receptor editing, and suit repeat dosing. Mesenchymal stromal cell products for immunological and inflammatory diseases, iPSC-derived platforms for long multi-dose courses, and treatment at sites unable to support autologous manufacture offer further openings. Key trends include approvals concentrating in products that act for a set period and are then cleared, a move from single curative infusions to repeat dosing (Ryoncil is given as eight infusions over four weeks), and a shift in starting material from donor collections to iPSC lines.
By cell type, the allogeneic cell therapy market is segmented into T cells (engineered receptor, regulatory, and virus-specific T cells), NK cells, mesenchymal stromal cells, hematopoietic stem & progenitor cells, dendritic cells, pancreatic islet cells, and other cell types. Hematopoietic stem & progenitor cells are expected to account for the largest share in 2026, as cord blood units and related products make up most approved donor-derived supply, transplantation is an established and reimbursed procedure, and banked units are available without a new collection. NK cells are expected to grow at the highest CAGR, because they lack the graft versus host disease risk of donor T cells, can be made from cord blood or iPSC lines without receptor editing, and clear quickly enough for repeat dosing to work. Mesenchymal stromal cells and islet cells each have an approved product, while approved T cell products are supplied with a transplant instead of as standalone infusions.
By source, the allogeneic cell therapy market is segmented into cord blood, peripheral blood, bone marrow, adipose tissue, placental & perinatal tissue, and induced pluripotent stem cell derived. Cord blood is expected to account for the largest share in 2026, supported by the number of approved cord blood products and by banks that supply units without a fresh donation for every patient. The iPSC-derived segment is expected to record the highest CAGR, as one line can be edited once and expanded indefinitely, which takes donor qualification and batch-to-batch comparison out of production and makes consistency a function of the process. No iPSC-derived product has been approved yet, while bone marrow is the source of Ryoncil and peripheral blood supports most engineered T cell and NK cell programs.
By gene modification, the allogeneic cell therapy market is segmented into non-gene-modified and gene-modified products. Non-gene-modified products are expected to account for the largest share in 2026, as nearly all approved allogeneic products, including cord blood units, processed tissue, Ryoncil, and Lantidra, are unmodified and already in clinical use. Gene-modified products are expected to grow at the highest CAGR, because the development pipeline is dominated by engineered receptor products and gene editing is the main way to keep donor T cells from attacking the recipient. This segment also has the least certain outlook, as its growth relies on indications where no allogeneic product has been approved.
By therapeutic area, the allogeneic cell therapy market is segmented into oncology (hematological malignancies and solid tumors), immunological & inflammatory diseases, cardiovascular diseases, musculoskeletal disorders, neurological disorders, metabolic & endocrine disorders, dermatology & wound care, and other therapeutic areas. Oncology is expected to account for the largest share in 2026, as blood cancers treated by transplantation consume most approved donor-derived supply and NK cell and engineered T cell development is focused on cancer. Immunological & inflammatory diseases are expected to grow at the highest CAGR, supported by Ryoncil's approval, the fit between short-acting stromal cells and inflammation-driven conditions, and treatment effects that can be measured within weeks, which lowers the evidence burden. Wound care relies on approved cultured skin substitutes, and metabolic disorders on Lantidra and iPSC-derived type 1 diabetes programs.
By end user, the allogeneic cell therapy market is segmented into hospitals & transplant centers, specialty clinics, and academic & research institutes. Hospitals & transplant centers are expected to account for the largest share in 2026, as transplantation requires conditioning, inpatient care, and complication management available only at these sites, where most approved products are given. Specialty clinics are expected to grow at the highest CAGR, because stocked products can be administered at any site with infusion and monitoring capability, free of the collection and manufacturing steps that keep autologous therapy within a few qualified centers. Academic & research institutes mainly supply investigational products under institutional authorization.
North America is expected to hold the largest share of the global allogeneic cell therapy market in 2026, supported by the number of donor-derived products approved by the FDA, a dense network of transplant centers and cord blood banks, and cell therapy reimbursement pathways that are more developed than elsewhere. The U.S. accounts for almost all of the regional market, with Canada contributing through transplant centers.
Asia-Pacific is expected to grow at the highest CAGR, driven by Japan's conditional approval pathway, which lets donor-derived products reach patients on earlier evidence, manufacturing investment in South Korea, China, and Singapore, and the many Chinese developers of allogeneic platforms. Japan holds the largest part of the regional market, followed by China, while South Korea adds patients and manufacturing capacity, and India and Australia add clinical activity. In Europe, the advanced therapy medicinal product framework and separate national reimbursement decisions mean access varies by member state; demand centers on Germany, France, Italy, Spain, and the U.K. Latin America and the Middle East & Africa remain small markets that depend on treatment abroad, private centers, and cord blood banking, with Israel standing out for development activity.
Holders of approved products in the allogeneic cell therapy market, such as cord blood banks, tissue engineering firms, and developers of stromal cell, islet cell, and regulatory T cell products, are largely separate from the engineered T cell, NK cell, and iPSC platform developers that attract most investment and have no approvals in those classes yet. Approved product holders have succeeded by choosing indications where cells need not persist, or where conditioning and matching allow engraftment, while manufacturing scale, donor supply, and regulatory experience separate the next tier. Large pharmaceutical companies have mostly entered through acquisitions and licensing with platform developers, so leadership in the engineered classes remains open.
Key companies profiled in the report include Mesoblast Limited (Australia), Orca Biosystems, Inc. (U.S.), Gamida Cell Ltd. (Israel), CellTrans Inc. (U.S.), Organogenesis Holdings Inc. (U.S.), Sumitomo Pharma Co., Ltd. (Japan), Humacyte, Inc. (U.S.), Neurotech Pharmaceuticals, Inc. (U.S.), Vertex Pharmaceuticals Incorporated (U.S.), Bayer AG (Germany), Allogene Therapeutics, Inc. (U.S.), Fate Therapeutics, Inc. (U.S.), Century Therapeutics, Inc. (U.S.), Caribou Biosciences, Inc. (U.S.), Nkarta, Inc. (U.S.), CRISPR Therapeutics AG (Switzerland), Healios K.K. (Japan), SanBio Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), and Pierre Fabre S.A. (France).
The market includes therapies made from donor cells instead of the patient's own cells, spanning T cell, natural killer (NK) cell, mesenchymal stromal cell, blood-forming stem and progenitor cell, dendritic cell, and islet cell products, along with corneal, chondrocyte, and keratinocyte tissue preparations. Cord blood units are counted only when released as licensed therapeutic products, and a product given with conditioning or supportive medicines is counted at the value of the cell product alone. Autologous cell therapies, gene therapies without a cell product, transfusion and plasma products, organ transplants, transplants of unmanipulated marrow or blood stem cells, private cord blood storage, manufacturing supplies, and the care delivered around treatment are excluded.
According to the FDA's list of approved cellular and gene therapy products, all seven approved CAR-T products, including Kymriah, Yescarta, and Carvykti, are autologous, and no allogeneic CAR-T therapy has been approved. FDA-approved donor-derived products are instead cord blood units, processed tissue products such as StrataGraft and Symvess, the islet cell therapy Lantidra, Omisirge, the mesenchymal stromal cell therapy Ryoncil, and the regulatory T cell immunotherapy Tregzi. The FDA approved Ryoncil in December 2024 for children with steroid-refractory acute graft versus host disease, describing it as the first approved mesenchymal stromal cell therapy; the approval rested on a single-arm study of 54 pediatric patients, 70% of whom responded by day 28. Revenue therefore comes mostly from classes other than the off-the-shelf CAR-T concept that draws most investment.
Market Dynamics
Lower cost per dose is the main driver of the allogeneic cell therapy market: one donor collection produces many doses, so batch cost is shared across patients, whereas each autologous treatment carries the full cost of a custom manufacture. Products that can be held in stock are a second driver, as a released batch is ready when a patient presents, which removes the wait and patient drop-off of autologous pathways and lets centers without collection and shipping logistics treat patients. Induced pluripotent stem cell (iPSC) lines, edited once and expanded without limit, remove the need to find and requalify donors, while approvals such as Ryoncil and Tregzi give developers regulatory precedents to design against.Immune rejection is the main restraint wherever cells must engraft and persist, as in CAR-T therapy, the most valuable class in cell therapy. Editing out the T cell receptor and using stronger lymphodepletion add toxicity, yet persistence still trails autologous products, and the barrier is biological, so manufacturing experience does not remove it. Donor dependence also narrows the cost advantage of products not made from iPSC lines, since each new donor brings qualification, testing, and comparability work. Developers must further prove durable responses against autologous products with years of follow-up and win reimbursement when lower production cost does not set a price on its own.
NK cell products are a leading opportunity, since NK cells avoid the graft versus host disease risk of donor T cells, need no receptor editing, and suit repeat dosing. Mesenchymal stromal cell products for immunological and inflammatory diseases, iPSC-derived platforms for long multi-dose courses, and treatment at sites unable to support autologous manufacture offer further openings. Key trends include approvals concentrating in products that act for a set period and are then cleared, a move from single curative infusions to repeat dosing (Ryoncil is given as eight infusions over four weeks), and a shift in starting material from donor collections to iPSC lines.
Segment Analysis
The report analyzes the market by cell type, source, gene modification, therapeutic area, end user, and geography, helping stakeholders identify the most attractive areas for development, partnering, and investment.By cell type, the allogeneic cell therapy market is segmented into T cells (engineered receptor, regulatory, and virus-specific T cells), NK cells, mesenchymal stromal cells, hematopoietic stem & progenitor cells, dendritic cells, pancreatic islet cells, and other cell types. Hematopoietic stem & progenitor cells are expected to account for the largest share in 2026, as cord blood units and related products make up most approved donor-derived supply, transplantation is an established and reimbursed procedure, and banked units are available without a new collection. NK cells are expected to grow at the highest CAGR, because they lack the graft versus host disease risk of donor T cells, can be made from cord blood or iPSC lines without receptor editing, and clear quickly enough for repeat dosing to work. Mesenchymal stromal cells and islet cells each have an approved product, while approved T cell products are supplied with a transplant instead of as standalone infusions.
By source, the allogeneic cell therapy market is segmented into cord blood, peripheral blood, bone marrow, adipose tissue, placental & perinatal tissue, and induced pluripotent stem cell derived. Cord blood is expected to account for the largest share in 2026, supported by the number of approved cord blood products and by banks that supply units without a fresh donation for every patient. The iPSC-derived segment is expected to record the highest CAGR, as one line can be edited once and expanded indefinitely, which takes donor qualification and batch-to-batch comparison out of production and makes consistency a function of the process. No iPSC-derived product has been approved yet, while bone marrow is the source of Ryoncil and peripheral blood supports most engineered T cell and NK cell programs.
By gene modification, the allogeneic cell therapy market is segmented into non-gene-modified and gene-modified products. Non-gene-modified products are expected to account for the largest share in 2026, as nearly all approved allogeneic products, including cord blood units, processed tissue, Ryoncil, and Lantidra, are unmodified and already in clinical use. Gene-modified products are expected to grow at the highest CAGR, because the development pipeline is dominated by engineered receptor products and gene editing is the main way to keep donor T cells from attacking the recipient. This segment also has the least certain outlook, as its growth relies on indications where no allogeneic product has been approved.
By therapeutic area, the allogeneic cell therapy market is segmented into oncology (hematological malignancies and solid tumors), immunological & inflammatory diseases, cardiovascular diseases, musculoskeletal disorders, neurological disorders, metabolic & endocrine disorders, dermatology & wound care, and other therapeutic areas. Oncology is expected to account for the largest share in 2026, as blood cancers treated by transplantation consume most approved donor-derived supply and NK cell and engineered T cell development is focused on cancer. Immunological & inflammatory diseases are expected to grow at the highest CAGR, supported by Ryoncil's approval, the fit between short-acting stromal cells and inflammation-driven conditions, and treatment effects that can be measured within weeks, which lowers the evidence burden. Wound care relies on approved cultured skin substitutes, and metabolic disorders on Lantidra and iPSC-derived type 1 diabetes programs.
By end user, the allogeneic cell therapy market is segmented into hospitals & transplant centers, specialty clinics, and academic & research institutes. Hospitals & transplant centers are expected to account for the largest share in 2026, as transplantation requires conditioning, inpatient care, and complication management available only at these sites, where most approved products are given. Specialty clinics are expected to grow at the highest CAGR, because stocked products can be administered at any site with infusion and monitoring capability, free of the collection and manufacturing steps that keep autologous therapy within a few qualified centers. Academic & research institutes mainly supply investigational products under institutional authorization.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 15 countries, the GCC countries, and four rest-of-region groups. The regional analysis considers approved product availability, transplant center and cord blood bank capacity, approval and reimbursement frameworks, manufacturing investment, and clinical development activity.North America is expected to hold the largest share of the global allogeneic cell therapy market in 2026, supported by the number of donor-derived products approved by the FDA, a dense network of transplant centers and cord blood banks, and cell therapy reimbursement pathways that are more developed than elsewhere. The U.S. accounts for almost all of the regional market, with Canada contributing through transplant centers.
Asia-Pacific is expected to grow at the highest CAGR, driven by Japan's conditional approval pathway, which lets donor-derived products reach patients on earlier evidence, manufacturing investment in South Korea, China, and Singapore, and the many Chinese developers of allogeneic platforms. Japan holds the largest part of the regional market, followed by China, while South Korea adds patients and manufacturing capacity, and India and Australia add clinical activity. In Europe, the advanced therapy medicinal product framework and separate national reimbursement decisions mean access varies by member state; demand centers on Germany, France, Italy, Spain, and the U.K. Latin America and the Middle East & Africa remain small markets that depend on treatment abroad, private centers, and cord blood banking, with Israel standing out for development activity.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share analysis, together with benchmarking by approved products and regulatory precedent and by platform, donor dependence, and manufacturing scale. Company profiles include business overviews, financial performance, product portfolios, strategic developments, and SWOT analyses.Holders of approved products in the allogeneic cell therapy market, such as cord blood banks, tissue engineering firms, and developers of stromal cell, islet cell, and regulatory T cell products, are largely separate from the engineered T cell, NK cell, and iPSC platform developers that attract most investment and have no approvals in those classes yet. Approved product holders have succeeded by choosing indications where cells need not persist, or where conditioning and matching allow engraftment, while manufacturing scale, donor supply, and regulatory experience separate the next tier. Large pharmaceutical companies have mostly entered through acquisitions and licensing with platform developers, so leadership in the engineered classes remains open.
Key companies profiled in the report include Mesoblast Limited (Australia), Orca Biosystems, Inc. (U.S.), Gamida Cell Ltd. (Israel), CellTrans Inc. (U.S.), Organogenesis Holdings Inc. (U.S.), Sumitomo Pharma Co., Ltd. (Japan), Humacyte, Inc. (U.S.), Neurotech Pharmaceuticals, Inc. (U.S.), Vertex Pharmaceuticals Incorporated (U.S.), Bayer AG (Germany), Allogene Therapeutics, Inc. (U.S.), Fate Therapeutics, Inc. (U.S.), Century Therapeutics, Inc. (U.S.), Caribou Biosciences, Inc. (U.S.), Nkarta, Inc. (U.S.), CRISPR Therapeutics AG (Switzerland), Healios K.K. (Japan), SanBio Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), and Pierre Fabre S.A. (France).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global allogeneic cell therapy market.
- Explains how batch economics, off-the-shelf supply, iPSC lines, and regulatory precedents are shaping growth.
- Assesses the impact of immune rejection, donor dependence, durability evidence, and reimbursement.
- Identifies high-growth opportunities across cell type, source, gene modification, therapeutic area, end user, and region.
- Tracks NK cell, gene-modified, and iPSC-derived programs and the shift toward repeat dosing.
- Benchmarks leading companies by approved products, regulatory precedent, platform, and manufacturing scale.
- Supports pipeline planning, partnering, licensing, and market entry decisions for developers, pharmaceutical companies, and investors.
Key Questions Answered
- How big is the global allogeneic cell therapy market today, and how will it grow through 2036?
- Which donor-derived products have been approved, and why has no allogeneic CAR-T therapy been approved?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How do immune rejection and graft versus host disease affect persistence and durability of response?
- How do batch size, donor qualification, and iPSC lines change the cost per dose?
- Which cell types, sources, therapeutic areas, and end users will grow the fastest?
- How do approval and reimbursement pathways in the U.S., Europe, and Japan affect access?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies, and how do they compare on approved products, platforms, and scale?
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Global Allogeneic Cell Therapy Market Assessment, by Cell Type
6. Global Allogeneic Cell Therapy Market Assessment, by Source
7. Global Allogeneic Cell Therapy Market Assessment, by Gene Modification
8. Global Allogeneic Cell Therapy Market Assessment, by Therapeutic Area
9. Global Allogeneic Cell Therapy Market Assessment, by End User
10. Global Allogeneic Cell Therapy Market Assessment, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Mesoblast Limited
- Orca Biosystems, Inc.
- Gamida Cell Ltd.
- CellTrans Inc.
- Organogenesis Holdings Inc.
- Sumitomo Pharma Co., Ltd.
- Humacyte, Inc.
- Neurotech Pharmaceuticals, Inc.
- Vertex Pharmaceuticals Incorporated
- Bayer AG
- Allogene Therapeutics, Inc.
- Fate Therapeutics, Inc.
- Century Therapeutics, Inc.
- Caribou Biosciences, Inc.
- Nkarta, Inc.
- CRISPR Therapeutics AG
- Healios K.K.
- SanBio Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Pierre Fabre S.A.
